Search alternatives:
point decrease » point increase (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 point » 5 point (Expand Search), _ point (Expand Search), a point (Expand Search)
point decrease » point increase (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 point » 5 point (Expand Search), _ point (Expand Search), a point (Expand Search)
-
641
-
642
Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.
Published 2025Subjects: -
643
Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.
Published 2025Subjects: -
644
Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.
Published 2025Subjects: -
645
-
646
-
647
Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.
Published 2025Subjects: -
648
Baseline patient characteristics across neutralizing monoclonal antibody trials.
Published 2025Subjects: -
649
-
650
-
651
-
652
-
653
-
654
-
655
-
656
-
657
Spatial information is significantly decreased in dCA1 and vCA1 in APP/PS1 mice.
Published 2024“…(B) In dCA1, spatial information was decreased in APP/PS1 mice relative to C57BL/6 controls (mean ± std: C57BL/6 = 0.132 ± 0.048, APP/PS1 = 0.128 ± 0.051, p < 0.005, two-sided Wilcoxon rank-sum test, n<sub>C57BL/6</sub> = 305 units from 5 recording sessions, n<sub>APP/PS1</sub> = 180 units from 4 recording sessions). …”
-
658
-
659
-
660